驱动力(838275) - 2023 Q4 - 年度业绩

Financial Performance - The company's operating revenue for 2023 is expected to be CNY 140.03 million, a decrease of 9.11% compared to the previous year[4] - The net profit attributable to shareholders is projected to be CNY 5.58 million, down 67.95% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be CNY 5.75 million, a decline of 49.92% from the previous year[4] - Total assets at the end of the reporting period are estimated to be CNY 237.72 million, a decrease of 5.66% compared to the previous year[5] - The company's equity attributable to shareholders is projected to be CNY 228.85 million, down 1.71% year-on-year[5] - Basic earnings per share are expected to decline by 67.95% due to the drop in net profit[8] Future Plans - The company plans to focus on the animal hematopoietic nutrition sector and increase new product R&D efforts in 2024[6] - The company emphasizes the importance of market demand changes and aims to stabilize and improve operating performance in the coming year[6] Risk Factors - The decrease in net profit is primarily attributed to a reduction in government subsidies by approximately CNY 5 million and an increase in credit impairment losses on accounts receivable[7] - Investors are advised to be cautious as the financial data presented is preliminary and subject to final audit[9]